Why Alterity Therapeutics (ASX:ATH) share price has surged up 27% today

The Alterity Therapeutics Ltd (ASX: ATH) share price has up 27% today after its neurodegenerative patent received approval in the US.

| More on:
miniature rocket breaking out of golden egg representing rocketing share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Alterity Therapeutics Ltd (ASX: ATH) share price has rocketed up 27% this morning after its patent was approved by the United States Patent and Trademark Office. At the time of writing, the Alterity share price is trading up at 3.3 cents.

Approval of US patent 

The new patent is the result of Alterity's in-house discovery research and is central to its next generation drug development portfolio focused on neurodegenerative diseases. 

Alterity's lead product, ATH434, is showing potential to treat various forms of atypical Parkinsonism. Parkinsonian disorders are a group of diseases in which individuals experience slowness of movement, stiffness and tremor. They include Parkinson's disease and Multiple System Atrophy, as well as Alzheimer's disease. The first disease target selected by Alterity is Multiple System Atrophy, a highly debilitating disease with no approved treatments. 

The US patent confers on Alterity 20 years of exclusivity, providing a strong basis for continued drug development and commercialisation and new compound identification within its extensive drug discovery library to target important neurodegenerative diseases. 

Commenting on the news, Alterity CEO Geoffrey Kempler said the patent established "an excellent foundation for the company to pursue multiple therapeutics across a spectrum of neurodegenerative disease".

The patent will allow the company to fully prosecute these opportunities with confidence in the coming years to address some of the most devastating brain diseases which currently have few or no treatment options. 

The day the Alterity share price jumped 2000% 

On 1 July 2020, the Alterity share price jumped more than 2000% from 1.7 cents to a peak of 41 cents before closing at 16.5 cents. This followed an announcement from the company that it had received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH43. 

Alterity met with the FDA following its successful Phase 1 clinical trial and further data analysis. The pre-IND (investigational new drug) meeting was to obtain input on the clinical development plan for ATH434, including feedback on the Phase 2 study design. 

Alterity reached an agreement with the FDA on the non-clinical investigations required to support the Phase 2 study. In parallel with its US strategy, the company also plans to pursue a regulatory pathway in Europe and Australia. 

Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
52-Week Highs

13 ASX 200 shares at 52-week highs

These shares are making their shareholders smile on Thursday.

Read more »

Five happy friends on their phones.
Share Market News

Goldman Sachs says these ASX tech stocks can rise 18% to 30%

The broker sees big returns on offer from these shares.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Happy woman looking for groceries. as she watches the Coles share price and Woolworths share price on her phone
Opinions

Why I bought this ASX 200 stock instead of Woolworths

I decided to put this stock in my shopping basket over Woolies.

Read more »

Excited woman holding out $100 notes, symbolising dividends.
Share Market News

Buy ANZ and this ASX dividend share now

Brokers have put buy ratings on these income options.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

It looks set to be a good session for Aussie investors today.

Read more »

A happy construction worker or miner holds a fistfull of Australian money, indicating a dividends windfall
Dividend Investing

Invest $12,000 in Woodside stock and get $5,700 in passive income

Reliable dividend shares are everywhere on the ASX. Here's how you could use that to your advantage.

Read more »